10-Q: Dror Ortho-Design Reports Increased R&D Spending and Net Losses in Q2 2024

Dror Ortho-Design reported increased research and development expenses and a net loss for the second quarter of 2024, as it continues to develop its orthodontic alignment platform.

Summary

• Dror Ortho-Design, Inc. reported a net loss of $1,506,790 for the three months ended June 30, 2024, and a net loss of $2,815,253 for the six months ended June 30, 2024.
• The company's research and development expenses increased to $389,216 for the three months ended June 30, 2024, and $762,873 for the six months ended June 30, 2024, due to increased development activities.
• General and administrative expenses also rose to $333,274 for the three months ended June 30, 2024, and $718,838 for the six months ended June 30, 2024, primarily due to increased salaries and professional fees.
• Share-based compensation expenses significantly increased to $774,428 for the three months ended June 30, 2024, and $1,311,625 for the six months ended June 30, 2024, due to the modification of outstanding stock options.
• The company's cash balance decreased to $1,834,477 as of June 30, 2024, from $3,347,843 at the end of 2023.
• The company has an accumulated deficit of $16,545,958 as of June 30, 2024, and is dependent on external financing.
• The company is planning to spend approximately $2.5 million over the next 18 months on software and hardware development, regulatory approvals, and IP protection.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses, a decreasing cash balance, and substantial doubt about the company's ability to continue as a going concern. While the company is developing a potentially disruptive technology, the financial risks and dependence on external funding are major concerns.

Positives

• The company is actively developing its proprietary AI-based orthodontic alignment platform.
• The company has several patents for the technology used in the platform.
• The company is preparing the prototype for FDA clearance.
• The company has a prior FDA clearance for a first-generation device, which may help with the new clearance process.

Negatives

• The company is currently not generating any revenue.
• The company has incurred significant net losses for both the three and six months ended June 30, 2024.
• The company's cash balance has decreased significantly.
• The company is dependent on external financing to continue operations.
• The company has a substantial accumulated deficit of $16,545,958 as of June 30, 2024.
• The company's financial statements are prepared on a going concern basis, with substantial doubt about its ability to continue as a going concern.

Risks

• The company is in the development stage and has no operating history in manufacturing and distributing orthodontic medical devices.
• The company's products and technologies may not be accepted by commercial consumers.
• The company faces competition from large, established aligner companies.
• The company's growth depends on its ability to enhance its platform and obtain regulatory clearance for new products.
• The company is subject to operating risks, including capacity constraints and operational inefficiencies.
• The company's products and IT systems are critical to its business, and issues with development or upgrades could disrupt operations.
• Complying with FDA and other regulatory authorities is expensive and time-consuming.
• The company may not receive the necessary authorizations to market its platform.
• The company's success depends on its proprietary technology and intellectual property rights.
• The company's management team has a relative lack of U.S. public company experience.
• The company's common stock is not listed on any stock exchange and has a limited market.
• The company's operations are conducted in Israel, and are subject to economic, political, geopolitical and military conditions in Israel.
• The ongoing conflict in Israel could disrupt the company's business and operations, interrupt its sources and availability of supplies, and hamper its ability to raise additional funds or sell its securities.

Future Outlook

The company intends to spend approximately $2.5 million over the next 18 months on software and hardware development, regulatory approvals, and IP protection. The company will need to raise additional capital to fund operating losses and grow its operations. There is no assurance that the company will be successful in raising these funds.

Management Comments

• Management believes that the financial institutions that hold the company's cash are financially sound.
• Management does not believe that inflation has had a material impact on the company's business, sales, or operating results during the periods presented.
• Management has substantial doubt about the company's ability to continue as a going concern.

Industry Context

The company is aiming to disrupt the aligner market with its proprietary AI-based platform, which offers a different approach to teeth alignment compared to traditional aligner solutions. The company faces competition from large, established aligner companies, such as Align Technology (Invisalign) and Straumann, which have a significant market presence and established distribution networks. The company's success will depend on its ability to gain market acceptance for its new technology and navigate the regulatory landscape.

Comparison to Industry Standards

• Dror Ortho-Design is in a pre-revenue stage, unlike established players like Align Technology (Invisalign) which reported $1 billion in revenue in Q1 2024, and Straumann which reported CHF 500 million in revenue in Q1 2024.
• The company's R&D spending is increasing as it develops its platform, which is typical for early-stage medical device companies. However, the company's R&D spending is significantly lower than that of larger companies like Align Technology, which invests hundreds of millions of dollars annually in R&D.
• The company's reliance on external funding is common for pre-revenue companies in the medical device sector. However, the company's going concern status highlights the significant financial risks it faces.
• The company's technology is focused on a different approach to teeth alignment, using a single smart aligner with pulsating air, which is different from the traditional multi-aligner approach used by Invisalign and other competitors. This could be a differentiator if the technology proves to be effective and gains market acceptance.
• The company's prior FDA clearance for a first-generation device is a positive factor, but the new platform requires a new 510(k) clearance, which is a significant regulatory hurdle.

Related Party Transactions

• The company has consulting agreements with directors Yehuda Englander and Chaim Ravad.
• The company has a consulting agreement with Oriole Avenue Inc., an entity owned by a stockholder of the company.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial losses and dependence on external funding.
• Employees may be affected by the company's financial instability and potential need to reduce activities.
• Customers may be impacted by delays in product development and regulatory approvals.
• Suppliers may face uncertainty due to the company's financial situation.
• Creditors face risk due to the company's financial losses and dependence on external funding.

Next Steps

• The company intends to spend approximately $2.5 million over the next 18 months on software and hardware development.
• The company is preparing the prototype for FDA clearance.
• The company will need to raise additional capital to fund operating losses and grow its operations.

Key Dates

Keywords

orthodontic alignment, medical device, AI platform, FDA clearance, research and development, share-based compensation, net loss, going concern, capital raise, Israel Innovation Authority